Products for Research Use Only

Pomalidomide-C5-Dovitinib

CAT: 0804-HY-139996Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-139996Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC containing Pomalidomide, Dovitinib and connected with CRBN. Pomalidomide-C5-Dovitinib shows enhanced antiproliferative effects against FLT3-ITD+ AML cells. Pomalidomide-C5-Dovitinib induces the degradation of the FLT3-ITD and KIT proteins in a ubiquitin-proteasome-dependent manner and completely blocks their downstream signaling pathway. Pomalidomide-C5-Dovitinib has the potential for the research of FLT3-ITD+ acute myeloid leukemia[1].
CAS Number
2732969-67-2
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Apoptosis; c-Fms; c-Kit; FGFR; FLT3; PDGFR; PROTACs; VEGFR
Type
Reference compound
Related Pathways
Apoptosis; PROTAC; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pomalidomide-c5-dovitinib.html
Solubility
10 mM in DMSO
Smiles
O=C1NC2=C(C(N)=C1C3=NC4=CC=C(N5CCN(CC5)C(CCCCCNC6=CC=CC(C(N7C8C(NC(CC8)=O)=O)=O)=C6C7=O)=O)C=C4N3)C(F)=CC=C2
Molecular Formula
C39H38FN9O6
Molecular Weight
747.77
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Cao S, et al. Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia Cells. J Med Chem. 2021;64 (22) :16497-16511.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported